呼吁采取行动:赋予药剂师在抗药性结核病管理中的权力
Mohammed Alfaqeeh1,2, Prayudi Santoso3, Jan-Willem Alffenaar4,5
1Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia.
Journal of multidisciplinary healthcare
|June 23, 2025
概括
药剂师在通过优化治疗和改善患者坚持治疗来管理耐药结核病 (DR-TB) 中发挥着至关重要的作用. 他们的专业知识对于克服治疗挑战和改善全球DR-TB患者的治疗结果至关重要.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 耐药结核病 (DR-TB) 仍然是一个重大的全球卫生挑战.
- 耐药结核病治疗的进展已经存在,但药剂师参与优化患者的治疗结果尚未完全实现.
研究的目的:
- 审查DR-TB类型,耐药性机制和管理策略.
- 突出药剂师在改善DR-TB患者治疗结果方面的关键作用.
主要方法:
- 采用了叙事审查方法.
- 从获取的文章中对参考列表进行手动审查.
主要成果:
- 耐药结核病包括各种形式,包括广泛耐药结核病 (XDR-TB).
- 关键的基因突变驱动了耐药性,影响了治疗的有效性.
- 药剂师可以提高药物的坚持,优化治疗方案,并指导治疗药物监测.
结论:
- 有效的DR-TB管理需要一个多方面的战略.
- 药剂师对于解决治疗复杂性,社会障碍和系统障碍至关重要.
- 优化药剂师角色是改善DR-TB护理患者治疗结果的关键.
相关概念视频
Pulmonary Tuberculosis V
249
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
249
Pulmonary Tuberculosis I
335
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
335
Pulmonary Tuberculosis IV
209
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
209
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Development of Antibiotic Resistance
232
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
232
Pneumonia IV: Management
458
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
458


